Unión Europea - lituano - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artritas, reumatas - imunosupresantai - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Unión Europea - lituano - EMA (European Medicines Agency)

seqirus netherlands b.v. - a/darwin/9/2021 (h3n2) - like strain (a/darwin/6/2021, ivr-227) / a/victoria/4897/2022 (h1n1) pdm09-like strain (a/victoria/4897/2022, ivr-238) / b/phuket/3073/2013-like strain (b/phuket/3073/2013, bvr-1b) / influenza virus b/austria/1359417/2021-like strain (b/austria/1359417/2021, bvr-26) - gripas, žmogus - vakcinos - profilaktikai gripo vyresnio amžiaus (65 metų amžiaus ir vyresni). fluad tetra turėtų būti naudojami laikantis oficialių rekomendacijų.

Unión Europea - lituano - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcinos - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.

Unión Europea - lituano - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - eprinomectin, esafoxolaner, praziquantel - eprinomectin, combinations, , avermectins, antiparasitic products, insecticides and repellents - katės - for cats with, or at risk from mixed infections by cestodes, nematodes and ectoparasites. veterinarinis vaistas yra tik nurodyta, kada visi trys grupes tuo pačiu metu.

Unión Europea - lituano - EMA (European Medicines Agency)

amarin pharmaceuticals ireland limited - icosapent ethyl - dislipidemijos - lipidą keičiančios medžiagos - indicated to reduce cardiovascular risk as an adjunct to statin therapy.

Unión Europea - lituano - EMA (European Medicines Agency)

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.

Unión Europea - lituano - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimetilfumaratas - išsėtinė sklerozė, grįžtamoji-pervedimo - imunosupresantai - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Lituania - lituano - SMCA (Valstybinė vaistų kontrolės tarnyba)

zoetis belgium sa (belgija) - liofilizatas - vienoje vakcinos dozėje yra: lukert padermės infekcinės bursos ligos virusų - ne mažiau kaip 104,3tcid50. - viščiukams (būsimiems broileriams, pakaitiniams, veisliniams paukščiams ir dedeklėms) vakcinuoti nuo infekcinės bursos (gamboro) ligos.

Lituania - lituano - SMCA (Valstybinė vaistų kontrolės tarnyba)

intervet international b.v. (nyderlandai) - liofilizatas - vienoje 1 ml dozėje yra: gyvo onderstepoort padermės šunų maro viruso (cdv) – ≥ 104,0  tcid50, gyvo manhattan lpv3 padermės 2 tipo šunų adenoviruso (cav2) – ≥ 104,0  tcid50, gyvo 154 padermės šunų parvoviruso (cpv) – ≥ 107,0  tcid50, gyvo cornell padermės šunų paragripo viruso (cpi) – ≥ 105,5  tcid50. - Šunims aktyviai imunizuoti, norint  sumažinti šunų maro viruso sukeliamos ligos klinikinius požymius; apsaugoti nuo šunų parvoviruso sukeliamų klinikinių požymių pasireiškimo ir viruso išskyrimo į aplinką;  sumažinti infekcinio šunų hepatito, sukeliamo 1 tipo šunų adenoviruso, klinikinius požymius ir viruso išskyrimą į aplinką;  sumažinti 2 tipo šunų adenoviruso ir šunų paragripo viruso sukeliamus kvėpavimo takų infekcijos klinikinius požymius ir virusų išskyrimą į aplinką.

Lituania - lituano - SMCA (Valstybinė vaistų kontrolės tarnyba)

zoetis belgium sa (belgija) - liofilizatas - vienoje vakcinos dozėje (1 ml) yra: nusilpnintų k padermės kalakutų infekcinio rinotracheito virusų - 103,2-104,5ccid50. * ccid50 = ląstelių kultūras užkrečianti 50% dozė. - kalakutams (broileriams) ir vištoms (broileriams) aktyviai imunizuoti, norint sumažinti infekcinio kalakutų rinotracheito (trt) klinikinių požymių pasireiškimą ir viruso išskyrimą. imuniteto pradžia: kalakutams 3 sav. po vakcinacijos. imuniteto trukmė: 14 sav.